Decorative spacer for background

APL-UW Home

University of Washington W Logo

Jobs
About
Campus Map
Contact
Privacy
YouTube
Facebook
Intranet

Jeff Thiel

APL Research Scientist/Engineer II

Email

jthiel@apl.uw.edu

Phone

206-221-4731

Education

B.S. Diagnostic Medical Ultrasound, Seattle University, 1992

Publications

2000-present and while at APL-UW

Fragmentation and facilitated clearance of small, asymptomatic, renal stones with burst wave lithotripsy and ultrasonic propulsion: A 14-month follow-up

Harper, J.D., B. Dunmire, J. Thiel, B.H. Burke, A.C. Desai, M. Dighe, B.J. Levchak, J.E. Lingeman, C.C.Yang, M.R. Bailey, Z. Liu, and M.D. Sorensen, "Fragmentation and facilitated clearance of small, asymptomatic, renal stones with burst wave lithotripsy and ultrasonic propulsion: A 14-month follow-up," J. Endourol., EOR, doi:10.1177/08927790261472744, 2026.

More Info

2 Aug 2026

Purpose:
To evaluate if treating small asymptomatic renal stones with office-based burst wave lithotripsy (BWL) and ultrasonic propulsion (UP) prevents future stone growth, emergency department visits, and surgical procedures for stone care.

Methods:
Participants with 2–7 mm asymptomatic renal stones were treated with BWL to break stones and UP to facilitate clearance of fragments. The primary outcome measure was relapse, defined as stone growth, an urgent or emergent medical visit, or operation for the randomized stones of interest within 14 months of the procedure. These events would include visits caused by the treatment and the presence of residual stones. Relapse data from untreated control groups with small stones or fragments from three published contemporaneous studies with similar protocols and 1- to 5-year follow-up were pooled and inverse probability weighted for comparison. The cumulative incidence of relapse was estimated using the Kaplan–Meier method.

Results:
Between April 2023 and September 2024, 18 participants underwent treatment of 27 asymptomatic small stones; 7 (39%) participants underwent a second BWL procedure to complete treatment. The control group had significantly shorter time to relapse than the treatment group (p = 0.048 by weighted log-rank test). The hazard ratio for relapse in the treatment group, compared with the control group, was less than 0.01 (p < 0.001). There was no relapse in the treated group within 14 months. For comparison, the 1-year relapse rate was 26% in the control group.

Conclusions:
In a small feasibility study, no stone-related relapse events occurred within 14 months following treatment of small, asymptomatic renal stones with BWL and UP.

Facilitated clearance of small, asymptomatic renal stones with burst wave lithotripsy and ultrasonic propulsion

Harper, J.D., and 18 others including B. Dunmire, J. Thiel, Y.-N. Wang, S. Totten, J.C. Kucewicz, and M.R. Bailey, "Facilitated clearance of small, asymptomatic renal stones with burst wave lithotripsy and ultrasonic propulsion," J. Urol., 214, 41-47, doi:10.1097/JU.0000000000004533, 2025.

More Info

1 Jul 2025

We tested feasibility of burst wave lithotripsy (BWL) and ultrasonic propulsion to noninvasively fragment and expel small, asymptomatic renal stones in awake participants.

Adult patients suspected of having 2- to 7-mm stones were consented and screened for eligibility. BWL and ultrasonic propulsion were applied to up to 3 stones in 1 kidney of qualifying participants for a 30-minute total exposure. Participants completed a CT scan and the Wisconsin Stone Quality-of-Life (WISQOL) questionnaire within 90 days before and 120 days after the procedure. Participants were contacted weekly for 3 weeks after the procedure to assess adverse events (AEs). Outcomes included (1) no fragment > 2 mm, (2) unanticipated health care visits, (3) change in stone volume, (4) reported AEs, and (5) WISQOL score.

Forty-one participants were enrolled between April 2023 and October 2024. Twenty-one participants failed screening because no stones were seen, stones were too large or small, stone visibility was too deep or obstructed, or they declined to participate. Twenty participants with 31 stones received the research procedure with 7 undergoing a single repeat procedure. Twenty-two of 31 stones (71%) met the primary effectiveness outcome of no fragment > 2 mm, with 17 of 31 stones (55%) reported as stone free. Median stone volume reduction (IQR) was 100% (88%–100%). No participants returned unexpectedly for care related to the procedure. AEs were all Grade I by modified Clavien classification. WISQOL scores improved on 10 of 15 completed questionnaires.

Small, asymptomatic renal stones were effectively and safely removed in awake participants in a clinic setting.

Advancing boiling histotripsy dose in ex vivo and in vivo renal tissues via quantitative histological analysis and shear wave elastography

Ponomarchuk, E., G. Thomas, M. Song, Y.-N. Wang, S. Totten, G. Schade, J. Thiel, M. Bruce, V. Khokhlova, and T. Khokhlova, "Advancing boiling histotripsy dose in ex vivo and in vivo renal tissues via quantitative histological analysis and shear wave elastography," Ultrasound Med. Biol., 50, 1936-1944, doi:10.1016/j.ultrasmedbio.2024.08.022, 2024.

More Info

1 Dec 2024

Objective
In the context of developing boiling histotripsy (BH) as a potential clinical approach for non-invasive mechanical ablation of kidney tumors, the concept of BH dose (BHD) was quantitatively investigated in porcine and canine kidney models in vivo and ex vivo.

Methods
Volumetric lesions were produced in renal tissue using a 1.5-MHz 256-element HIFU-array with various pulsing protocols: pulse duration tp = 1–10 ms, number of pulses per point ppp = 1–15. Two BHD metrics were evaluated: BHD1 = ppp, BHD2 = tp × ppp. Quantitative assessment of lesion completeness was performed by their histological analysis and assignment of damage score to different renal compartments (i.e., cortex, medulla, and sinus). Shear wave elastography (SWE) was used to measure the Young's modulus of renal compartments in vivo vs ex vivo, and before vs after BH treatments.

Results
In vivo tissue required lower BH doses to achieve identical degree of fractionation as compared to ex vivo. Renal cortex (homogeneous, low in collagen) was equal or higher in stiffness than medulla (anisotropic, collagenous), 5.8–12.2 kPa vs 4.7–9.6 kPa, but required lower BH doses to be fully fractionated. Renal sinus (fatty, irregular, with abundant collagenous structures) was significantly softer ex vivo vs in vivo, 4.9–5.1 kPa vs 9.7–15.2 kPa, but was barely damaged in either case with any tested BH protocols. BHD1 was shown to be relevant for planning the treatment of renal cortex (sufficient BHD1 = 5 pulses in vivo and 10 pulses ex vivo), while none of the tested doses resulted in complete fractionation of medulla or sinus. Post-treatment SWE imaging revealed reduction of tissue stiffness ex vivo by 27–58%, increasing with the applied dose, and complete absence of shear waves within in vivo lesions, both indicative of tissue liquefaction.

Conclusion
The results imply that tissue resistance to mechanical fractionation, and hence required BH dose, are not solely determined by tissue stiffness but also depend on its composition and structural arrangement, as well as presence of perfusion. The SWE-derived reduction of tissue stiffness with increasing BH doses correlated with tissue damage score, indicating potential of SWE for post-treatment confirmation of BH lesion completeness.

More Publications

Acoustics Air-Sea Interaction & Remote Sensing Center for Industrial & Medical Ultrasound Electronic & Photonic Systems Environmental & Information Systems Ocean Engineering Ocean Physics Polar Science Center
Close

 

Close